Drugs / INT131
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02638038 | Feb 2015 → Dec 2016 | relapsing-remitting multiple sclerosis | InteKrin Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00631007 | Feb 2008 → Aug 2009 | type 2 diabetes mellitus | InteKrin Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00952445 | Dec 2003 → Jun 2004 | type 2 diabetes mellitus | InteKrin Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INT131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02638038 ↗ |
| Known as | AMG-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236924 ↗ |
| Known as | CHS-131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236924 ↗ |
| Known as | Ibrigampar | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236924 ↗ |
| Known as | INT131 besylate | “OBJECTIVE: INT131 besylate is a potent, nonthiazolidinedione, selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM) designed to improve glucose...” PMID 24722496 ↗ Apr 2014 |
| Known as | T0903131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00952445 ↗ |
| Known as | T131 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236924 ↗ |
| Modality | Other / unclassified | “INT131 besylate is a potent, nonthiazolidinedione, selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM)” PMID 24722496 ↗ Apr 2014 |
| Route | Oral | “Once-daily, oral” NCT00631007 ↗ |
| Target | PPARG | “selective peroxisome proliferator-activated receptor γ (PPARγ) modulator” PMID 24722496 ↗ Apr 2014 |